NCT04183868View on ClinicalTrials.gov

Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions

Type 2 DiabetesCardiovascular Risk Factor

Interventions

DRUG

Empagliflozin 10 MG

10 mg tablet daily

DRUG

Glimepiride 2 mg

starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily

Trial Locations (1)

88100

Universital Hospital Mater Domini, Catanzaro

All Listed Sponsors

lead

University of Catanzaro

OTHER

NCT04183868 - Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study) | Biotech Hunter | Biotech Hunter